The pharmaceutical industry under increasing pressure to reduce time and capital in developing drugs would greatly benefit from Conagen’s development of a fermentation-based technology it acquired for the production of therapeutically useful glycoproteins. The host platform will be used by Conagen for development of both novel and generic drugs.